Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can stem cells restore fertility in early menopause?

NCT ID NCT03816852

Disease control Sponsor: Sclnow Biotechnology Co., Ltd. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused This study
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether stem cells from umbilical cords can safely help women with premature ovarian failure (early menopause). Twelve participants receive stem cell infusions, and doctors monitor menstrual cycles, hormone levels, and follicle growth. The goal is to see if this treatment can restore ovarian function better than standard hormone therapy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 12 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2018

Expected to finish

Jun 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

19 to 40 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Meet diagnostic criteria of European Society of Human Reproduction and Embryology * No hormonotherapy and chinese traditional medicine within 3 months; * Understand and sign informed consent. Exclusion Criteria: * Patient with congenital adrenocortical hyperplasia; * Patient with Cushing syndrome; * Patient with Thyroid dysfunction; * Patient with hyperprolactinemia; * Patient with pituitary amenorrhea or hypothalamic amenorrhea; * Patient with HIV, hepatitis; * Gene defect (eg. Turner syndrome, fragile X syndrome) * Serious drug allergy history; * Suffering from thrombophlebitis, thromboembolism including venous thrombosis and arterial thrombosis; * History of treatment of ovarian cysts or ovarian surgery * With high tumor marker; * Pregnant or lactating * Receive other treatments that may affect the efficacy and safety of stem cells; * Do not understand or without sign informed consent; * The attending physician believes that it is not suitable for participating in this trial

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Premature ovarian failure are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

premature menopause primary ovarian failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Premature ovarian failure

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Henan Provincial People's Hospital

    Zhengzhou, Henan, 450003, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.